St Jude Medical has announced that it has completed its acquisition of privately held NeuroTherm, a manufacturer of interventional pain management therapies.
NeuroTherm is a global leader in the treatment of spinal pain using radiofrequency ablation (RFA), a segment of the chronic pain market in which St Jude Medical does not currently participate. NeuroTherm’s flagship technology is a multi-lesion radiofrequency generator that allows real-time temperature monitoring and enables continuous delivery of energy to each site designed to ensure complete treatment of each targeted spinal nerve. The company’s products are available in over 65 countries.
“Over the last year, we have launched two novel neuromodulation products, made a strategic investment in Spinal Modulation, and initiated two multicentre, randomised clinical studies to evaluate alternatives for patients living with chronic pain,” says Michael T Rousseau, St Jude Medical chief operating officer. “This acquisition further demonstrates St Jude Medical’s commitment to our chronic pain programme and our steadfast focus on improving patient outcomes.”
St Jude Medical is the only medical device manufacturer with a chronic pain product portfolio that offers both radiofrequency ablation for spinal pain and spinal cord stimulation. The company now has a comprehensive range of radiofrequency products available worldwide for interventional pain management, including generators, electrodes and needles.